Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19
Abstract Despite the success of existing COVID-19 vaccine platforms, the persistent limitations in global deployment of vaccines and waning immunity exhibited by many of the currently deployed vaccine platforms have led to perpetual outbreaks of SARS-CoV-2 variants of concern. Thus, there is an urge...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-02-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-023-00612-2 |
| _version_ | 1797420798113218560 |
|---|---|
| author | Paulina Kaplonek Deniz Cizmeci Jessica Shih-Lu Lee Sally A. Shin Stephanie Fischinger Philipe Gobeil Stéphane Pillet Nathalie Charland Brian J. Ward Galit Alter |
| author_facet | Paulina Kaplonek Deniz Cizmeci Jessica Shih-Lu Lee Sally A. Shin Stephanie Fischinger Philipe Gobeil Stéphane Pillet Nathalie Charland Brian J. Ward Galit Alter |
| author_sort | Paulina Kaplonek |
| collection | DOAJ |
| description | Abstract Despite the success of existing COVID-19 vaccine platforms, the persistent limitations in global deployment of vaccines and waning immunity exhibited by many of the currently deployed vaccine platforms have led to perpetual outbreaks of SARS-CoV-2 variants of concern. Thus, there is an urgent need to develop new durable vaccine candidates, to expand the global vaccine pipeline, and provide safe and effective solutions for every country worldwide. Here we deeply profiled the functional humoral response induced by two doses of AS03-adjuvanted and non-adjuvanted plant-derived Coronavirus-like particle (CoVLP) vaccine candidate from the phase 1 clinical trial, at peak immunogenicity and six months post-vaccination. AS03-adjuvanted CoVLP induced robust and durable SARS-CoV-2 specific humoral immunity, marked by strong IgG1antibody responses, potent FcγR binding, and antibody effector function. Contrary to a decline in neutralizing antibody titers, the FcγR2A-receptor binding capacity and antibody-mediated effector functions, such as opsonophagocytosis, remained readily detectable for at least six months. |
| first_indexed | 2024-03-09T07:07:44Z |
| format | Article |
| id | doaj.art-d55dbfe42ce74d4cbb08ac3c06582bd4 |
| institution | Directory Open Access Journal |
| issn | 2059-0105 |
| language | English |
| last_indexed | 2024-03-09T07:07:44Z |
| publishDate | 2023-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj.art-d55dbfe42ce74d4cbb08ac3c06582bd42023-12-03T09:27:50ZengNature Portfolionpj Vaccines2059-01052023-02-018111110.1038/s41541-023-00612-2Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19Paulina Kaplonek0Deniz Cizmeci1Jessica Shih-Lu Lee2Sally A. Shin3Stephanie Fischinger4Philipe Gobeil5Stéphane Pillet6Nathalie Charland7Brian J. Ward8Galit Alter9Ragon Institute of MGH, MIT, and HarvardRagon Institute of MGH, MIT, and HarvardRagon Institute of MGH, MIT, and HarvardRagon Institute of MGH, MIT, and HarvardRagon Institute of MGH, MIT, and HarvardMedicago Inc.Medicago Inc.Medicago Inc.Medicago Inc.Ragon Institute of MGH, MIT, and HarvardAbstract Despite the success of existing COVID-19 vaccine platforms, the persistent limitations in global deployment of vaccines and waning immunity exhibited by many of the currently deployed vaccine platforms have led to perpetual outbreaks of SARS-CoV-2 variants of concern. Thus, there is an urgent need to develop new durable vaccine candidates, to expand the global vaccine pipeline, and provide safe and effective solutions for every country worldwide. Here we deeply profiled the functional humoral response induced by two doses of AS03-adjuvanted and non-adjuvanted plant-derived Coronavirus-like particle (CoVLP) vaccine candidate from the phase 1 clinical trial, at peak immunogenicity and six months post-vaccination. AS03-adjuvanted CoVLP induced robust and durable SARS-CoV-2 specific humoral immunity, marked by strong IgG1antibody responses, potent FcγR binding, and antibody effector function. Contrary to a decline in neutralizing antibody titers, the FcγR2A-receptor binding capacity and antibody-mediated effector functions, such as opsonophagocytosis, remained readily detectable for at least six months.https://doi.org/10.1038/s41541-023-00612-2 |
| spellingShingle | Paulina Kaplonek Deniz Cizmeci Jessica Shih-Lu Lee Sally A. Shin Stephanie Fischinger Philipe Gobeil Stéphane Pillet Nathalie Charland Brian J. Ward Galit Alter Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19 npj Vaccines |
| title | Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19 |
| title_full | Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19 |
| title_fullStr | Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19 |
| title_full_unstemmed | Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19 |
| title_short | Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19 |
| title_sort | robust induction of functional humoral response by a plant derived coronavirus like particle vaccine candidate for covid 19 |
| url | https://doi.org/10.1038/s41541-023-00612-2 |
| work_keys_str_mv | AT paulinakaplonek robustinductionoffunctionalhumoralresponsebyaplantderivedcoronaviruslikeparticlevaccinecandidateforcovid19 AT denizcizmeci robustinductionoffunctionalhumoralresponsebyaplantderivedcoronaviruslikeparticlevaccinecandidateforcovid19 AT jessicashihlulee robustinductionoffunctionalhumoralresponsebyaplantderivedcoronaviruslikeparticlevaccinecandidateforcovid19 AT sallyashin robustinductionoffunctionalhumoralresponsebyaplantderivedcoronaviruslikeparticlevaccinecandidateforcovid19 AT stephaniefischinger robustinductionoffunctionalhumoralresponsebyaplantderivedcoronaviruslikeparticlevaccinecandidateforcovid19 AT philipegobeil robustinductionoffunctionalhumoralresponsebyaplantderivedcoronaviruslikeparticlevaccinecandidateforcovid19 AT stephanepillet robustinductionoffunctionalhumoralresponsebyaplantderivedcoronaviruslikeparticlevaccinecandidateforcovid19 AT nathaliecharland robustinductionoffunctionalhumoralresponsebyaplantderivedcoronaviruslikeparticlevaccinecandidateforcovid19 AT brianjward robustinductionoffunctionalhumoralresponsebyaplantderivedcoronaviruslikeparticlevaccinecandidateforcovid19 AT galitalter robustinductionoffunctionalhumoralresponsebyaplantderivedcoronaviruslikeparticlevaccinecandidateforcovid19 |